Adjust Font Sizing:

Blog Post

Stay Hydrated This Summer

While exposure to light is supposed to promote “alertness”, it’s not uncommon to feel tired or even sluggish after spending time outside. There are many factors that […]

Listening Journey: Our Collective Voice Matters

Last year, Narcolepsy Network began a “Listening Journey” to better understand our organization’s individual and collective interests. We also sought out the perspectives of medical professionals and industry […]

Clinical Research Matters: Takeaways From World Sleep Congress 2022

by Keith Harper, Board President Last week, Amy Kant, Transition Director, and I traveled to Rome for the 2022 World Sleep Congress, an event put together by […]

Suddenly Sleepy Saturday is March 12, 2022

  Help Raise Narcolepsy Awareness with Suddenly Sleepy Saturday Suddenly Sleepy Saturday, also known as Narcolepsy Awareness Day, will take place on March 12, 2022. Narcolepsy Network encourages […]

Transition Leadership Announcement

The voice of people with narcolepsy is the heart of Narcolepsy Network. Since we announced leadership changes in February, we are continuing to deliver on current programs […]

An Update from the Board of Directors

Dr. Eveline Honig was with Narcolepsy Network for the last 16 years, aiding in its mission to provide education, support, and advocacy for patients and families impacted […]

Virtual Mini-Conferences

Join us for our next free Virtual Mini-Conference, which will be held on Saturday, April 24 at 2:00 PM ET/11:00 AM PT. The theme will be Finding Your […]

Update on the COVID-19 Vaccine

We asked Dr. Michael Thorpy, a member of our Medical Advisory Board from the Sleep-Wake Disorders Center in New York if people with narcolepsy should get the […]

Donate to Make Twice the Impact

Thanks to a few generous donors, if you make a donation before January 1, 2021, they will match your gift up to $10,000. This means your donation […]

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA

Avadel Pharmaceuticals plc announced the submission of its New Drug Application to the US Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium […]